ArticleWorld journal of gastroenterology2006
Effects of interleukin-10 on activation and apoptosis of hepatic stellate cells in fibrotic rat liver.
Article in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives.International journal of pharmaceutics · 2024Review
- Pancreatic stellate cells: Key players in pancreatic health and diseases (Review).Molecular medicine reports · 2024Review
- Efferocytosis in liver disease.JHEP reports : innovation in hepatology · 2024Review
- Isolation and Biological Evaluation of Alfa-Mangostin as Potential Therapeutic Agents against Liver Fibrosis.Bioengineering (Basel, Switzerland) · 2023Article
- Resveratrol increases the activation markers and changes the release of inflammatory cytokines of hepatic stellate cells.Molecular and cellular biochemistry · 2021Article
- Targeting Certain Interleukins as Novel Treatment Options for Liver Fibrosis.Frontiers in pharmacology · 2021Review
- The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis.Advances in wound care · 2020Review
- Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer.Journal of Cancer · 2020Review
- Vascular endothelial growth factor promotes the activation of hepatic stellate cells in chronic schistosomiasis.Immunology and cell biology · 2017Article
- The Synthetic Triterpenoid RTA 405 (CDDO-EA) Halts Progression of Liver Fibrosis and Reduces Hepatocellular Carcinoma Size Resulting in Increased Survival in an Experimental Model of Chronic Liver Injury.Toxicological sciences : an official journal of the Society of Toxicology · 2016Article
- IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-β receptor on hepatic stellate cells in a JNK-dependent manner.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Changes in the expression of genes related to apoptosis and fibrosis pathways in CCl4-treated rats.Molecular and cellular biochemistry · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the effects of interleukin-10 (IL-10) on the expression of alpha-smooth muscle actin (alpha-SMA), nuclear factor- kappa B(NF- kappa B) and Fas/Fas ligand (FasL) in hepatic stellate cells of experimental rats with hepatic fibrosis.
methodsSixty clean SD rats were randomly divided into control group (group N), liver fibrotic group (group C) and IL-10 treatment group (group I). Control group received intraperitoneal injection of saline (2 mL/kg), twice a week. Fibrotic group was injected intraperitoneally with 50% carbon tetrachloride (CCl(4)) (2 mL/kg), twice a week. IL-10 treatment group was given IL-10 at a dose of 4 microg/kg 20 minutes before CCl(4) administration from the third week. Hepatic stellate cells (HSCs) were isolated from these rats at the seventh and eleventh weeks during the course of liver fibrosis, respectively. The expression of alpha-SMA and NF- kappa B in HSCs was measured by S-P immunohistochemistry. The expression of Fas and FasL mRNA was measured by RT-PCR. Furthermore, liver tissues were harvested from three groups at the same time.
resultsThe CCl(4)- induced experimental rat hepatic fibrosis model was established successfully. The purity of extracted hepatic stellate cells was about 95% and the yield of hepatic stellate cells was 1.2-2.3 x 10(6)/g liver tissue averagely. The positive expression of alpha-SMA and NF- kappa B was 36.5% and 28.5% respectively in group N. The positive levels of alpha-SMA and NF- kappa B were increased significantly in group C compared to group N (P<0.01). The positive signals decreased significantly (P<0.05) in group I. In the 11th week, the HSCs of group I became round with visible pyknotic nuclei. The expression of NF- kappa B in group C was significantly increased in a time-dependent manner (P<0.01), but there was no difference in the alpha-SMA expression (P>0.05). The mRNA of Fas and FasL in group C was significantly increased in a time-dependent manner compared to that in control group. After treated with IL-10, the expression level of Fas and FasL was higher in group I than in group C.
conclusionThe positive expression of alpha-SMA and NF- kappa B in hepatic stellate cells is decreased by ectogenic IL-10 in liver fibrosis induced by CCl(4). The expression of Fas and FasL is increased in the course of liver fibrosis, and is further increased by IL-10. IL-10 could inhibit the activation of HSCs and cause apoptosis of activated HSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.